A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection

Trial Profile

A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs TT 034 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; First in man
  • Sponsors Tacere Therapeutics
  • Most Recent Events

    • 28 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 03 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 25 Apr 2016 Interim results published in the Benitec media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top